S
2.15
-0.05 (-2.27%)
| Previous Close | 2.20 |
| Open | 2.15 |
| Volume | 113,139 |
| Avg. Volume (3M) | 150,234 |
| Market Cap | 28,200,262 |
| Price / Earnings (TTM) | 3.26 |
| Price / Earnings (Forward) | 21.83 |
| Price / Sales | 81.97 |
| Price / Book | 0.340 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -34,814.94% |
| Diluted EPS (TTM) | 0.660 |
| Quarterly Revenue Growth (YOY) | -58.70% |
| Total Debt/Equity (MRQ) | 4.70% |
| Current Ratio (MRQ) | 1.05 |
| Operating Cash Flow (TTM) | -7.03 M |
| Levered Free Cash Flow (TTM) | -6.06 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -35.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Pharmaceutical Retailers (US) | Mixed | Mixed |
| Pharmaceutical Retailers (Global) | Mixed | Bearish | |
| Stock | Scienture Holdings, Inc. | - | - |
AIStockmoo Score
0.0
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S. |
|
| Sector | Healthcare |
| Industry | Pharmaceutical Retailers |
| Investment Style | Small Core |
| % Held by Insiders | 32.59% |
| % Held by Institutions | 1.35% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jul 2025 | Announcement | Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding |
| 16 Jul 2025 | Announcement | Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements |
| 17 Jun 2025 | Announcement | Scienture Holdings Announces Cancelation of ELOC |
| 22 May 2025 | Announcement | SCIENTURE Announces Executive Leadership Transition |
| 19 May 2025 | Announcement | SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. |
| 1Y Average Dividend Yield | 157.03% |
| Expected Next Dividend Payment | Jul 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 19 Jul 2024 | 08 Jul 2024 | 24 Jul 2024 | 1.5 Cash |
| 25 Mar 2024 | 28 Feb 2024 | 22 Mar 2024 | 8 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 9.50 | 2 | 157.03 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |